Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caffo Orazio, Ortega Cinzia, Di Lorenzo Giuseppe, Sava Teodoro, De Giorgi Ugo, Cavaliere Carla, Macrini Sveva, Spizzo Gilbert, Aieta Michele, Messina Caterina, Tucci Marcello, Lodde Michele, Mansueto Giovanni, Zucali Paolo Andrea, Alesini Daniele, D'Angelo Alessandro, Massari Francesco, Morelli Franco, Procopio Giuseppe, Ratta Raffaele, Fratino Lucia, Lo Re Giovanni, Pegoraro Maria Cristina, Zustovich Fable, Vicario Giovanni, Ruatta Fiorella, Federico Piera, La Russa Francesca, Burgio Salvatore Luca, Maines Francesca, Veccia Antonello, Galligioni Enzo
Аннотация
PATIENTS AND METHODS: We retrospectively identified 134 patients who were 60 years and younger who were treated with docetaxel in 25 Italian hospitals and recorded their predocetaxel history of prostate cancer, their characteristics at the start of chemotherapy, and their postdocetaxel treatment history and outcomes.
RESULTS: Most of the 134 consecutive patients with mCRPC received the standard 3-week docetaxel schedule; median progression-free survival (PFS) was 7 months, and 90 patients underwent further therapies after progression. The median overall survival (OS) from the start of docetaxel treatment was 21 months, but OS was significantly prolonged by the postprogression treatments, particularly those based on the new agents such as cabazitaxel, abiraterone acetate, or enzalutamide. OS was significantly shorter in the patients with a shorter interval between the diagnosis of prostate cancer and the start of docetaxel treatment; those who received hormonal treatment for a shorter period; those with shorter prostate-specific antigen doubling times; and those with lower hemoglobin levels, a worse performance status, and higher lactate dehydrogenase levels before starting treatment with docetaxel.
CONCLUSIONS: The findings of this first study of clinical outcomes in a contemporary series of younger patients with mCRPC showed that their survival is similar to that expected in unselected patients with mCRPC who were of any age.